Targeted Treatment Helps Delay ALK+ mNSCLC Progression
Remarkable progress has been made in the treatment of ALK+ mNSCLC patients, and the field continues to grow at a rapid pace.
Read More
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC